T2D AID Intel
Competitive Ops
Competitors

Tracked competitors in the T2D AID space

Click any card to open the full dossier — field guide, narrative shifts, pricing, marketing, churn risk, threats, and live market data.

Insulet

PODD

Omnipod 5

0SoV · 30d
86
Threat
62
30d momentum
T138%·T245%
Share (T1 / T2)
ApprovedTubeless patch425K usersSource · methodology

Tandem Diabetes Care

TNDM

t:slim X2 / Mobi (Control-IQ+)

0SoV · 30d
74
Threat
41
30d momentum
T124%·T218%
Share (T1 / T2)
ApprovedTubed micro-pump215K usersSource · methodology

MiniMed

MMNM

MiniMed 780G (SmartGuard) — formerly Medtronic Diabetes

0SoV · 30d
71
Threat
18
30d momentum
T126%·T222%
Share (T1 / T2)
FiledTubed pump310K usersSource · methodology

Beta Bionics

BBNX

iLet Bionic Pancreas

0SoV · 30d
58
Threat
73
30d momentum
T18%·T25%
Share (T1 / T2)
In trialTubed pump28K usersSource · methodology

Sequel Med Tech

twiist (Tidepool Loop)

0SoV · 30d
47
Threat
88
30d momentum
T14%·T21%
Share (T1 / T2)
In trialTubed micro-pump4K usersSource · methodology

New Entrants

Emerging T2D AID players (watchlist)

0SoV · 30d
32
Threat
55
30d momentum
T10%·T29%
Share (T1 / T2)
Pre-clinicalTubeless patch0K usersSource · methodology

Share-of-segment — T1 vs T2 distribution

How each competitor stacks within the Type 1 and Type 2 markets.

Type 1
Type 2
InsuletTandemMiniMedBetaSequelNew